Over the past decades, the emergence of immunotherapies has changed the game in cancer treatment. However, immunotherapies so far have only shown efficacy in certain patient populations and suffer from a high degree of off-tumor activity due to lack of tumor selectivity. This severely compromises efficacy and safety of these promising therapies.
Targeting tumors with MHC-specific antibodies
CDR-Life is developing new immunotherapies that target antigens restricted to tumor cells, thereby, solving the problem of non-tumor selectivity with existing treatments. We designed a new antibody-based approach that targets highly cancer-specific proteins that exist inside the tumor cells. Intracellular tumor proteins are presented to the immune system as peptides on Major Histocompatibility Complex (MHC), which are natural targets of in cancer cells.
Based on more than 20 years of expertise in cutting-edge antibody fragment design, engineering and production, we have developed a technology to generate antibodies binding to tumor-specific peptides on MHC with very high specificity. Combined with our proprietary multi-specific format, we are developing truly tumor-specific and -eradicating T cell engagers.